Table 5 Anti-malarial prescription practice in both study arms showing the frequency of use of different ACT and non-ACT drugs within each study group
Antimalarial dispensed | Intervention pharmacy (frequency and % antimalarials within study arm) n = 360 | Control pharmacy (frequency and % antimalarials within study arm) n = 607 |
|---|---|---|
Artemether-Lumefantrine | 180 | 337 |
(50.0%) | (55.5%) | |
Artesunate-Amodiaquine | 42 | 47 |
(11.7%) | (7.7%) | |
Dihydroartemisinin-Piperaquine | 30 | 33 |
(8.3%) | (5.4%) | |
Artesunate-Sulfadoxine-Pyrimethamine | 8 | 12 |
(2.2%) | (2.0%) | |
ACT (total) | 260 | 429 |
(72.2%) | (70.6%) | |
Sulfadoxine-Pyrimethamine alone | 39 | 75 |
(10.8%) | (12.4%) | |
Artesunate alone | 47 | 58 |
(13.1%) | (9.6%) | |
Chloroquine alone | 13 | 30 |
(3.6%) | (4.9%) | |
Quinine alone | 1 | 15 |
(0.3%) | (2.5%) | |
Non-ACT (total) | 100 | 178 |
(27.8%) | (29.4%) |